Expertise in
10
conditions

Karin Hartmann

1Department Of Dermatology, Ratzeburger Allee 160, 
Luebeck, SH, DE 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
10
conditions
1Department Of Dermatology, Ratzeburger Allee 160, 
Luebeck, SH, DE 

Overview

Karin Hartmann practices practicing medicine in Luebeck, Germany.

Ms. Hartmann is highly rated in 10 conditions, according to our data. Her clinical expertise encompasses Mast Cell Activation Syndrome (MCAS), Systemic Mastocytosis, Anaphylaxis, and Urticaria Pigmentosa.

She is actively involved in clinical research, co-authoring 189 peer reviewed articles and participating in 4 clinical trials.

Gender

Female

Locations

1Department Of Dermatology, Ratzeburger Allee 160, Luebeck, SH 23538, Germany
Other Locations
Kerpener Str. 62, Koeln, NW 50937, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis
A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis
Enrollment Status: Recruiting
Publish Date: August 04, 2026
Intervention Type: Drug
Study Drug: BLU-263
Study Phase: Phase 2/Phase 3
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Outpatient Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Baricitinib in Pediatric Patients With Moderate to Severe Atopic Dermatitis
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Outpatient Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Baricitinib in Pediatric Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: August 05, 2026
Intervention Type: Drug
Study Drugs: Baricitinib, Topical Corticosteroid
Study Phase: Phase 3
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy
Enrollment Status: Active_not_recruiting
Publish Date: September 23, 2025
Intervention Type: Drug
Study Drug: Avapritinib
Study Phase: Phase 2
A Three-year, Non-interventional, Prospective, Multicenter Study to Evaluate the Long- Term Effectiveness of Lanadelumab in Real-world Clinical Practice (ENABLE)
A Three-year, Non-interventional, Prospective, Multicenter Study to Evaluate the Long- Term Effectiveness of Lanadelumab in Real-world Clinical Practice (ENABLE)
Enrollment Status: Completed
Publish Date: September 02, 2025
View 3 Less Clinical Trials

189 Total Publications

Subtype-specific outcome after allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis: a registry study of the European competence network on mastocytosis.
Subtype-specific outcome after allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis: a registry study of the European competence network on mastocytosis.
Journal: Experimental hematology & oncology
Published: June 21, 2026

Frequently Asked Questions about Karin Hartmann

Is Karin Hartmann a top-rated expert for Mast Cell Activation Syndrome (MCAS)?

MediFind is an objective health platform that identifies experts based on real-world data. Karin Hartmann is classified as an Elite expert for Mast Cell Activation Syndrome (MCAS), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Karin Hartmann participate in research or clinical trials?

Yes. Karin Hartmann has published 189 articles and abstracts on conditions like Mast Cell Activation Syndrome (MCAS). You can view a list of Karin Hartmann's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Hartmann's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 19 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile